In fact, IC14, a chimeric monoclonal antibody, is a potential anti-CD14 therapeutic agent that has been investigated in COVID-19 patients.17 Thus, IC14 may also be useful for treatment of gout by blocking the interactions of CD14, DAMPs and MSU, thereby attenuating the NLRP3/IL-1β pathway. This evidence concerns the gene NLRP3 and gout.